Biotech investor Brad Loncar shares 10 predictions for 2022, including a 30% rebound for biotech, the year's biggest M&A deal, and CEOs who won't last the year
Pharma companies are always searching for the next big cancer therapies.
Last year, Loncar highlighted drugs targeting a protein called CD47 as promising for companies building out their oncology presence. He predicted two CD47 biotechs would be bought in 2021 and was partially right, with Pfizerfor $2.2 billion. Now, he has his eyes on another target protein called TIGIT.
Instead, their transformative benefits have been limited to a small group of patients. A major limitation has been manufacturing because cells need to be extracted from a patient, edited in a lab, and then reinfused.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
2022 job market predictions according to CareerBuilder CEOCareerBuilder expects a major influx of activity at the start of the New Year, and its CEO makes predictions for the job market in 2022|
Baca lebih lajut »
2022 Mercedes-Benz AMG EQS, 2022 Nio ET5, 2023 Maserati MC20 convertible: This Week's Top PhotosAMG's newest EV, Nio's Tesla Model 3 rival, and a Maserati supercar all made headlines this week.
Baca lebih lajut »
Blackpink’s Jennie Just Shared a Sneak Peek of Her New Gentle Monster Eyewear CollaborationBlackpink's Jennie Just Shared a Sneak Peek of Her New Gentle Monster Eyewear Collaboration
Baca lebih lajut »
The Top 20 Most-Anticipated TV Shows of 2022 That We Can't Wait to Watch2022 is already looking like a golden year for TV. ✨
Baca lebih lajut »
Self Esteem singer Rebecca Taylor is 'so ready to be overrated' after award winsRebecca Taylor has had a successful 2021 and is hoping to be even bigger in 2022
Baca lebih lajut »